Meeting Demand for Weight Loss Drugs

Novo Nordisk CEO expects years to meet high demand for Wegovy weight loss drug.
Limited starter doses of Wegovy create supply challenges as demand soars.
The company invests up to $4 billion annually in manufacturing expansion to meet demand.
Wegovy, containing semaglutide, has shown substantial weight loss benefits and heart benefits in studies.
High demand for Wegovy extends globally as it becomes available in more countries.
Challenges include the cost of the drug and the need for ongoing treatment to maintain weight loss, with some safety concerns under scrutiny.